Use of bisphosphonate therapy for osteoporosis in childhood and adolescence
Use of bisphosphonate therapy for osteoporosis in childhood and adolescence
复制标题
DOI：
10.1046/j.1440-1754.2003.00083.x
复制
发表时间：
2003-03-01
影响因子：
1.7
通讯作者：
Zacharin, M
中科院分区：
文献类型：
--
作者：
Batch, JA;Couper, JJ;Zacharin, M
儿童和青春期先天和后天形式的骨质疏松症可导致儿童时期骨折和疼痛的发病率，并使个人在成年后面临严重问题的风险。有一系列预防和治疗骨质疏松症的疗法，包括优化每日钙摄入量、充足的维生素D状态、负重运动、在青春期延迟的情况下使用性类固醇治疗，以及最近使用双磷酸盐疗法。静脉注射帕米磷酸钠(一种双膦酸盐)已被证明能减少骨折并改善成骨不全儿童的骨密度，并可能被证明对儿童时期的其他骨质疏松状况有好处。然而，关于儿童和青少年最佳使用双膦酸盐疗法的一些问题仍有待解决，包括年总剂量、给药频率和持续时间。因此，双膦酸类药物治疗应仅在具有儿童骨质疏松症管理专业知识的良好运行的临床方案的背景下使用。
Congenital and acquired forms of osteoporosis in childhood and adolescence can result in morbidity from fracture and pain in childhood, and place an individual at significant risk for problems in adult life. A range of therapies exist for the prevention and treatment of osteoporosis, including optimization of daily calcium intake, adequate vitamin D status, weight-bearing exercise, treatment with sex steroids where delayed puberty is a problem and, more recently, use of bisphosphonate therapy. Intravenous pamidronate therapy (a bisphosphonate) has been shown to reduce fractures and improve bone density in children with osteogenesis imperfecta, and might prove to be of benefit in other osteoporotic conditions in childhood. However, a number of issues regarding the optimal use of bisphosphonate therapy in children and adolescents remain to be resolved, including total annual dose and frequency and duration of administration. Bisphosphonate therapy should, therefore, be used only in the context of a well-run clinical programme with specialist knowledge in the management of osteopenic disorders in childhood.